Clinical Trial Detail

NCT ID NCT02107703
Title A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib

Fulvestrant

Age Groups: adult

Additional content available in CKB BOOST